Citations

Clear

16280 citation(s) found for "Yu, David".

Faculty Opinions recommendation of The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 31, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717847858.793352825 Get It

Faculty Opinions recommendation of Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 31, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717949502.793454702 Get It

Faculty Opinions recommendation of Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.
Katzka, David A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 31, 2012 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717949500.793454700 Get It

Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802
Shaw, Edward G. , Wang, Meihua , Coons, Stephen W., Brachman, David, Buckner, Jan C. , Stelzer, K. , Barger, Geoffrey, Brown, Paul D. , Mehta, Minesh P. , Gilbert, Mark R. , Mehta, Minesh P

Mayo Clinic

Journal of Clinical Oncology | July 31, 2012 | Volume: 30 | Issue: 25 | Pages: 3065-3070

10.1200/jco.2011.35.8598 | PMID 22851558 Get It

Purpose A prior Radiation Therapy Oncology Group (RTOG) clinical trial in anaplastic oligodendroglioma suggested a progression-free survival benefit for procarbazine, lomustine, and vincristine (PCV) chemotherapy in addition to radiation therapy (RT), as have smaller trials in low-grade glioma (LGG). Patients and Methods Eligibility criteria included supratentorial WHO grade 2 LGG, age 18 to 39 years with subtotal resection/biopsy, or age ≥ 40 years with any extent resection. Patients were randomly assigned to RT alone or RT followed by six cycles of PCV. Survival was compared by using the modified Wilcoxon and log-rank tests. Results In all, 251 patients were accrued from 1998 to 2002. Median overall survival (OS) time and 5-year OS rates for RT versus RT + PCV were 7.5 years versus not reached and 63% versus 72%, respectively (hazard ratio [HR]; 0.72; 95% CI, 0.47 to 1.10; P = .33; log-rank P = .13). Median progression-free survival (PFS) time and 5-year PFS rates for RT versus RT + PCV were 4.4 years versus not reached and 46% versus 63%, respectively (HR, 0.6; 95% CI, 0.41 to 0.86; P = .06; log-rank P = .005). OS and PFS were similar for all patients between years 0 and 2. After 2 years, OS and PFS curves separated significantly, favoring RT + PCV. For 2-year survivors (n = 211), the probability of OS for an additional 5 years was 74% with RT + PCV versus 59% with RT alone (HR, 0.52; 95% CI, 0.30 to 0.90; log-rank P = .02). Conclusion PFS but not OS was improved for adult patients with LGG receiving RT + PCV versus RT alone. On post hoc analysis, for 2-year survivors, the addition of PCV to RT conferred a survival advantage, suggesting a delayed benefit for chemotherapy.
An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
Vij, Ravi , Stewart, Alexander K., McDonagh, Kevin T., Belch, Andrew R. , Kunkel, Lori, Wear, Sandra, Wang, Michael , Siegel, David S. , Jagannath, Sundar , Jakubowiak, Andrzej , Bahlis, Nizar Jacques , Wong, Alvin , Orlowski, Robert Z.

Mayo Clinic

British Journal of Haematology | July 30, 2012 | Volume: 158 | Issue: 6 | Pages: 739-748

10.1111/j.1365-2141.2012.09232.x | PMID 22845873 Get It

SummaryCarfilzomib is a next‐generation proteasome inhibitor that selectively and irreversibly binds to its target. In clinical studies, carfilzomib has shown efficacy in patients with relapsed and/or refractory multiple myeloma (MM) and has demonstrated a tolerable safety profile. In this phase 2, open‐label, multicentre clinical trial, 35 patients with relapsed and/or refractory MM following 1–3 prior therapies, including at least one bortezomib‐based regimen, received carfilzomib 20 mg/m2 in a twice‐weekly, consecutive‐day dosing schedule for ≤12 monthly cycles. The best overall response rate (ORR) was 17·1% and the clinical benefit response rate (ORR + minimal response) was 31·4%. The median duration of response was >10·6 months and the median time to progression was 4·6 months. The most common adverse events were fatigue (62·9%), nausea (60·0%), and vomiting (42·9%). No exacerbation of baseline peripheral neuropathy was observed. Single‐agent carfilzomib was generally well tolerated for up to 12 treatment cycles and showed activity in patients with relapsed and/or refractory MM who had received prior treatment with bortezomib. These data, combined with an acceptable toxicity profile, support the potential use of carfilzomib in patients with relapsed and/or refractory MM and warrant continued investigation of carfilzomib as single agent or in combination with other agents.
Cerecyte Coil Trial
Molyneux, Andrew , Clarke, Alison, Sneade, Mary , Mehta, Ziyah, Coley, Stuart C., Kallmes, David F. , Fox, Allan J. , Roy, Daniel C.

Mayo Clinic

Stroke | July 27, 2012 | Volume: 43 | Issue: 10 | Pages: 2544-2550

10.1161/strokeaha.112.657254 | PMID 22836352 Get It

Background and Purpose— We report the primary outcome of the Cerecyte Coil Trial, a randomized trial to determine whether polymer-loaded Cerecyte coils compared with Micrus bare platinum coils improved the proportion of patients with angiographic occlusion of the aneurysm at 6 months when assessed by a core laboratory. The secondary objectives were to compare the clinical outcomes and retreatment rates in the 2 groups. Methods— Five hundred patients between 18 and 70 years of age with a ruptured or unruptured target aneurysm were randomized to be treated with either Cerecyte or bare platinum coils in 23 centers worldwide. Two hundred forty-nine patients were assigned to Cerecyte coils and 251 to bare platinum coils. Analysis was by intention to treat. Results— Four hundred ninety-four patients were eligible for analysis. Four hundred eighty-one patients underwent coil treatment of their aneurysm, 227 patients with recently ruptured aneurysms and 254 with unruptured aneurysms. Four hundred thirty-three follow-up angiograms were assessed by the core laboratory; 127 of 215 (59%) and 118 of 218 (54%) in the Cerecyte and bare platinum groups, respectively, fulfilled the trial prespecified definition of success, namely that the treated aneurysm showed complete angiographic occlusion, had stable neck remnant, or improved in angiographic appearance compared with the end-of-treatment angiogram ( P =0.17). Late retreatment was performed in 25 of 452 (5.5%) patients, 17 (7.7%) Cerecyte versus 8 (3.5%) bare platinum ( P =0.064; range, 4–34 months). The clinical outcomes did not differ between the groups. Conclusion— There was no significant difference at 6 months in the angiographic outcomes between Cerecyte coils and bare platinum coils when assessed by the core laboratory. Clinical Trial Registration Information— URL: www.controlled-trials.com . Unique Identifier: ISRCTN82461286.
Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases
Blitterswijk, Marka van , Vlam, Lotte, Doormaal, Perry T.C. van , Seelen, Meinie, Medic, Jelena, Dooijes, Dennis , Visser, Marianne de, Kooi, Anneke J. van der , Raaphorst, Joost , Schelhaas, Helenius J. , Pol, W. Ludo van der , Veldink, Jan H. , Berg, Leonard H. van den , Aisen, Paul , Petersen, Ronald C., Clifford, R. Jack, Jagust, William, Trojanowki, John Q., Liu, Enchi , Montine, Tom, Gamst, Anthony, Thomas, Ronald G. , Walter, Sarah , Gessert, Devon, Sather, Tamie, Harvey, Danielle, Kornak, John , Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene, DeCarli, Charles, Bandy, Dan, Foster, Norm, Reiman, Eric M., Mathis, Chet, Cairns, Nigel J. , Taylor‐Reinwald, Lisa, Shaw, Les, Korecka, Magdalena , Crawford, Karen , Neu, Scott, Foroud, Tatiana, Potkin, Steven, Kachaturian, Zaven, Frank, R.T., Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James B., Vanderswag, Helen, Heidebrink, Judith L. , Petersen, Ronald C. , Johnson, Kris , Doody, Rachelle S., Villanueva‐Meyer, Javier , Chowdhury, Munir , Honig, Lawrence S., Bell, Karen L. , Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Grossman, Hillel, Mitsis, Effie, Romirowsky, Aliza, deToledo‐Morrell, Leyla, Duara, Ranjan , Varón, Daniel , Roberts, Peggy, Albert, Marilyn , Onyike, Chiadi U. , Kielb, Stephanie , Glodzik, Lidia , Doraiswamy, P. Murali , Petrella, Jeffrey R. , Arnold, Steven E. , Karlawish, Jason H., Smith, Charles D., Hardy, P. , Lopez, Oscar L., Oakley, MaryAnn, Simpson, Donna M., Ismail, M. Saleem, Brand, Connie, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Swerdlow, Russell H. , Bartzokis, George, Lu, Po H. , Apostolova, Liana G. , Graff‐Radford, Neill R. , Parfitt, Francine, Farlow, Martin, Herring, Scott, Hake, Ann Marie , Dyck, Christopher H. van , Carson, Richard E. , MacAvoy, Martha G., Chertkow, Howard, Bergman, Howard , Hosein, Chris, Black, Sandra, Caldwell, Curtis, Assaly, Michele, Kertesz, Andrew , Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Wu, Chuang‐Kuo, Johnson, Nancy E., Mesulam, Marsel, Sadowsky, Carl, Villena, Teresa, Johnson, Kathleen A., Reynolds, Brigid, Sperling, Reisa A., Frey, Meghan , Johnson, Keith A. , Rosen, Allyson , Tinklenberg, Jared, Belden, Christine M. , Jacobson, Sandra A. , Wolday, Saba, Bwayo, Salome K., Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Kittur, Smita, Borrie, Michael, Lee, T‐Y, Bartha, Robert , Asthana, Sanjay , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Hendin, Barry , Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Blank, Karen, Anderson, Karen, Santulli, Robert B. , Schwartz, Eben S., Williamson, Jeff D. , Watkins, Franklin, Ott, Brian R. , Querfurth, Henry, Tremont, Geoffrey , Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J., Mintzer, Jacobo , Longmire, Crystal Flynn, Spicer, Kenneth, Kwon, Sun-Uck, Kim, Joon‐Tae , Cho, Ki-Hyun , Ko, Y.J., Lee, Soo Joo , Cha, Jae-Kwan, Shin, Dong-Jin, Jang, Hyuk Jae, Choi, Nack‐Cheon , Hong, Seok-Chang, Rha, Joung-Ho, Kim, Eung‐Gyu , Choi, Jay Chol , Shin, Won Chul , HyukHeo, Sung, Chung, Kyung Cheon, Lee, Jun Hong , Bae, Hee‐Joon , Lee, Tae‐Kyeong , Jeong, Dushin, Lee, Jun , Ashwal, Steve, deVeber, Gabrielle , Ichord, Rebecca , Kirkham, Fenella J. , Lynch, John K., O’Callaghan, Finbar , Pavlakis, Steve, Sébire, Guillaume , Willan, Andrew R. , Dlamini, Noma, Nowak-Göttl, Ulrike, Düring, Christine, Plumb, Patricia , Journeycake, Janna M., Bruinhorst, Katrina van de, Gossett, Daniel R., Chavez, Marta Isabel Hernandez, Barnes, Chris , Furmedge, Janine, Gordon, Anne , Benedict, Susan, Bale, James F. , Nielson, Denise, Kabbouche, Marielle A., Karti, Pooja, Phillips, Tonya, Rizkallah, Élie, Zamel, Khaled, Wiznitzer, Max , Lidsky, Karen , Bernard, Timothy J. , Goldenberg, Neil A. , Booth, Frances, Nash, Monica, Beslow, Lauren A. , Carpenter, Jessica L. , Weinstein, Steven L., Li, Kan , Smith, Robin, Maytal, Joseph, Sy-Kho, Rosemarie, Yager, Jerome Y. , Massicotte, Patti, McClure, Chalmer, Hukin, Juliet, Bucevska, Marija, Kent, Sheila, Riviello, James J. , Rivkin, Michael, Trenor, Cameron C. , Whelan, Harry T. , Goodman, Sharon, Levinson, Kim, Kolk, Anneli , Laugesaar, Rael , Talvik, Tiina, Imam, Hussain, Thomas, Terrence , Kirton, Adam , Ganesan, Vijeya , Saengpattrachai, Montri, Crosswell, Hal E., Mancuso, Ann, Yeh, E. Ann , Humpherys, Peter, Abraham, Lisa , Alveal, Lucila Andrade, Ortiz, Manuel Arriaza, Altuna, Diana, Maxit, Clarisa, González, Verónica , Alam, Muhammad Rafiqul , Buckley, David , Penney, Sharon, Grabowski, Eríc F. , Deray, Marcel J., Khatib, Zaid, Kosofsky, Barry E. , Leifer, Dana , Nass, Ruth, Wong, Virginia, Catsman, Coriene E. , El-Hakam, Lisa Michael, Cholette, Jill M., Narang, Shalu, Lerner, Norma B., Carpenter, Shannon L. , Bischoff, Kurt, Frei‐Jones, Melissa , Masur, David, Gallentine, William B., Rende, Elizabeth K., Provenzale, James, Voyvodic, James , Song, Allen W. , Conklin, Terrie, O’Hara, Kathryn, Seinfeld, Syndi, Conry, Joan A. , Ayala, Jennifer , Facchini, Ronda, Sigalova, Maryana, Hannigan, James, Mancini, Ann , Curran, John S. , Ahlm, Sarah, Renaldi, J., Umanzour, Diana K, Kim, Andrew, Hamidullah, Aaliyah, Litherland, Claire , Bonner, Melanie, Xu, Yuan , Water, Virginia Van de, Grasso, Susan, Culbert, James, Bush, Brian J., Chandrasekaran, Sreedevi, Davis, Lori L. , Rogers, Christiane, Sabo, Cynthia , Wang, Helen H. , Lee, Ting‐Yim , Rheenen, Wouter van , Huisman, Mark H. B. , Weiner, Michael D. , Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Saykin, Andrew J. , Morris, John C. , Donohue, Michael , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Koeppe, Robert A. , Reiman, Eric M. , Chen, Kewei , Mathis, Chet, Lee, Virginia M.‐Y. , Shen, Li , Snyder, Peter J. , Kaye, Jeffrey , Quinn, Joseph F. , Lord, Joanne L. , Stern, Yaakov , Honig, Lawrence S. , Clark, David , Grossman, Hillel, Shah, Raj C. , Duara, Ranjan , Rusinek, Henry , Leon, Mony J. de , Karlawish, Jason , Wolk, David A. , Jicha, Gregory A. , Lopez, Oscar L., Diaz‐Arrastia, Ramon , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather K. , Farlow, Martin R. , Stefanovic, Bojana , Hsiung, Ging‐Yuek Robin , Feldman, Howard , Martínez, Walter Fabián , Turner, Raymond Scott , Sabbagh, Marwan Noel , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Fletcher, Evan M. , Carmichael, Owen , Johnson, Sterling C. , Carlsson, Cynthia M. , Potkin, Steven G. , Preda, Adrian , Nguyen, Dana R. , Scharre, Douglas W. , Pearlson, Godfrey D. , Sink, Kaycee M. , Miller, Bruce L. , Shin, Dong‐Ick , Kim, Yong‐Jae , Rha, Joung‐Ho , Hong, Keun‐Sik , Sohn, Sung‐Il , Park, Jong‐Ho , Park, Jong‐Moo , Park, Tai Hwan , Han, Moon‐Ku , Kwon, Hyung‐Min , Lee, Kyung‐Bok , Ashwal, Steven, Ferriero, Donna Marie , Fullerton, Heather J. , Lynch, John K., Sofronas, Marianne , Elbers, Jorina M. , Krümpel, Anne , Monagle, Paul , Mackay, Mark T. , Abdalla, Abdalla , Chadehumbe, Madeline , Friedman, Neil , Armstrong, Jennifer , Chang, Taeun , Sy-Kho, Rose Marrie, Björnson, Bruce , Hukin, Juliette , Amlie‐Lefond, Catherine , Fox, Christine K. , Golomb, Meredith R. , Heyer, Geoffrey L. , Tatishvili, Nana Nino , Jordan, Lori C. , Chan, Anthony K.C. , Kovacevic, Gordana S. , Epstein, Leon G. , Bagiella, Emilia , Hinton, Veronica J. , Voyvodic, James T., Glauser, Tracy A. , Weiss, Erica F , Kushner, David B. , BUSH, BRIAN J. , Noebels, Jeffrey L. , van Blitterswijk, Marka , Veldink, Jan H

Mayo Clinic

Neurology | July 27, 2012 | Volume: 79 | Issue: 9 | Pages: 878-882

10.1212/wnl.0b013e3182661d14 | PMID 22843265 Get It

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
Martin, Thomas G. , Wang, Michael , Vij, Ravi , Trudel, Suzanne , Kukreti, Vishal , Alsina, Melissa , Chanan‐Khan, Asher , Reu, Frederic J. , Somlo, George, Zonder, Jeffrey A. , Song, Kevin , Stewart, A. Keith, Stadtmauer, Edward A. , Kunkel, Lori, Wear, Sandra, Orlowski, Robert Z. , Siegel, David S. , Jakubowiak, Andrzej , Lonial, Sagar , Bahlis, Nizar Jacques , Buadi, Francis K. , Wong, Alvin , Orlowski, Robert Z. , Jagannath, Sundar , Reu, Frederic J

Mayo Clinic

Blood | July 26, 2012 | Volume: 120 | Issue: 14 | Pages: 2817-2825

10.1182/blood-2012-05-425934 | PMID 22833546 Get It

AbstractCarfilzomib is a next-generation, selective proteasome inhibitor being evaluated for the treatment of relapsed and refractory multiple myeloma. In this open-label, single-arm phase 2 study (PX-171-003-A1), patients received single-agent carfilzomib 20 mg/m2 intravenously twice weekly for 3 of 4 weeks in cycle 1, then 27 mg/m2 for ≤ 12 cycles. The primary endpoint was overall response rate (≥ partial response). Secondary endpoints included clinical benefit response rate (≥ minimal response), duration of response, progression-free survival, overall survival, and safety. A total of 266 patients were evaluable for safety, 257 for efficacy; 95% were refractory to their last therapy; 80% were refractory or intolerant to both bortezomib and lenalidomide. Patients had median of 5 prior lines of therapy, including bortezomib, lenalidomide, and thalidomide. Overall response rate was 23.7% with median duration of response of 7.8 months. Median overall survival was 15.6 months. Adverse events (AEs) were manageable without cumulative toxicities. Common AEs were fatigue (49%), anemia (46%), nausea (45%), and thrombocytopenia (39%). Thirty-three patients (12.4%) experienced peripheral neuropathy, primarily grades 1 or 2. Thirty-three patients (12.4%) withdrew because of an AE. Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clinical benefit. This trial was registered at www.clinicaltrials.gov as #NCT00511238.
IC‐P‐030: MRI and MRS predictors of MCI in a population‐based sample of cognitively normal older adults
Weigand, Stephen D. , Przybelski, Scott A. , Preboske, Gregory M., Senjem, Matthew L. , Murphy, Matthew P., Roberts, Rosebud O., Petersen, Ronald C. , Kantarci, Kejal , Pankratz, V. Shane , Geda, Yonas E. , Boeve, Bradley F. , Knopman, David S. , Jack, Clifford R. , Senjem, Matthew L

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_1 | Pages: No page available

10.1016/j.jalz.2012.05.062 Get It